May 15, 2020 / 7:49 AM / 22 days ago

BRIEF-Hofseth Biocare: Preclinical Research With OmeGo Demonstrates Potential To Treat Eosinophilic Asthma

May 15 (Reuters) - Hofseth Biocare ASA:

* REG-HOFSETH BIOCARE ASA: PRECLINICAL RESEARCH WITH OMEGO® DEMONSTRATES POTENTIAL TO TREAT EOSINOPHILIC ASTHMA

* OMEGO® CONTAINS MINOR LIPID-SOLUBLE COMPONENTS THAT HAVE BEEN SHOWN TO REDUCE EOSINOPHIL EFFECTOR FUNCTION (EEF) AND INCREASE EOSINOPHIL APOPTOSIS (PROGRAMMED CELL DEATH) IN VARIOUS INVITRO CELLULAR ASSAYS AT 100 UG/ML CONCENTRATIONS.

* WE WILL CONTINUE TO DEVELOP THIS INDICATION BY PROGRESSING TOWARDS PRE-CLINICAL ANIMAL TRIALS IN Q3 2020,

* WE ANTICIPATE THAT THIS WILL LEAD TO INITIATION OF PHASE 1 CLINICAL TRIAL WORK IN ASTHMA DURING 2021 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below